Study S003193

Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Knee Osteoarthritis (AMAZE 5)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07481630
Acronym: AMAZE 5
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 400
Start: 2026-04-13
Primary completion: 2028-08-14
Lead sponsor: Novo Nordisk A/S
Conditions: Obesity; Knee Osteoarthritis (OA)
Interventions: DRUG:NNC0487-0111; DRUG:Placebo (matched to NNC0487-0111 )
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1313-6585; OTHER:2024-520444-42

Registered primary outcomes

Relative change in body weight [From baseline (week 0) to (week 80)]
Change in WOMAC Osteoarthritis Index NRS 3.1 (24-hour) (WOMAC) pain score [From baseline (week 0) to (week 80)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.